Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors
Qing Wei, Peijing Li, Teng Yang, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 54

Showing 1-25 of 54 citing articles:

Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents
Ali Doostmohammadi, Hossein Jooya, Kimia Ghorbanian, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 36
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
Raffaele Colombo, Paolo Tarantino, Jamie R. Rich, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2089-2108
Closed Access | Times Cited: 19
Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets
Fan Guan, Ruixuan Wang, Zhenjie Yi, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 3
Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed/refractory AML: preclinical evaluation and phase I trial
Ruihao Huang, Xiaoqi Wang, Hongju Yan, et al.
Experimental Hematology and Oncology (2025) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice
Ling Zhou, Yunlong Lu, Wei Liu, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 11
Cisplatin-eugenol Pt(IV) prodrugs target colon cancer stem cells: A novel strategy for enhanced anticancer efficacy
Vojtěch Novohradský, Tomer Babu, Hana Kostrhunová, et al.
Biomedicine & Pharmacotherapy (2025) Vol. 183, pp. 117854-117854
Closed Access | Times Cited: 1
Synergistic Interactions Between Probiotics and Anticancer Drugs: Mechanisms, Benefits, and Challenges
Babak Pezeshki, Hussein T. Abdulabbas, Asma M. Alturki, et al.
Probiotics and Antimicrobial Proteins (2025)
Closed Access | Times Cited: 1
Supramolecular 3 in 1: A Lubrication and Co-Delivery System for Synergistic Advanced Osteoarthritis Therapy
Mengmeng Chen, Y H Li, Yu‐Jie Zhu, et al.
ACS Nano (2024) Vol. 18, Iss. 20, pp. 13117-13129
Closed Access | Times Cited: 7
Antibody-Drug Conjugates in Urothelial Cancer: From Scientific Rationale to Clinical Development
Whi‐An Kwon, Seo Yeon Lee, Tae Cheon Jeong, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2420-2420
Open Access | Times Cited: 6
Intercellular adhesion molecule-1 (ICAM-1): From molecular functions to clinical applications in cancer investigation
Wen‐Jing Qian, Jinshan Yan, Xiaoyu Gang, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 6, pp. 189187-189187
Closed Access | Times Cited: 6
Economics of Antibody Drug Conjugates (ADCs): Innovation, Investment and Market Dynamics
Arya Bhushan, Preeti Misra
Current Oncology Reports (2024) Vol. 26, Iss. 10, pp. 1224-1235
Closed Access | Times Cited: 5
Precision targeting in oncology: The future of conjugated drugs
Jiahe Li, Lei Liu, Xihe Zhao
Biomedicine & Pharmacotherapy (2024) Vol. 177, pp. 117106-117106
Closed Access | Times Cited: 4
Tissue factor targeted near-infrared photoimmunotherapy: a versatile therapeutic approach for malignancies
Seiichiro Takao, Hiroshi Fukushima, Aki Furusawa, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 2
Open Access
The role of monoclonal antibodies in the treatment of pancreatic and colon cancers
Soumya Dakshinamurthy
Elsevier eBooks (2025), pp. 389-412
Closed Access
Antibody-drug conjugate combinations in cancer treatment: clinical efficacy and clinical study perspectives
X. Shi, Kai Tang, Quanbin Zhang, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Global research progress in antibody-drug conjugates for solid tumors: Bibliometrics and visualized analysis
Wenjun Fang, Xueqing Ma, Ben Liu
Human Vaccines & Immunotherapeutics (2025) Vol. 21, Iss. 1
Open Access
Opportunities and Challenges in Antibody–Drug Conjugates for Cancer Therapy: A New Era for Cancer Treatment
Idil Buyukgolcigezli, Ateş Kutay Tenekeci, Ibrahim Halil Sahin
Cancers (2025) Vol. 17, Iss. 6, pp. 958-958
Open Access
Mirvetuximab soravtansine: current and future applications
Beihua Kong, Wenxin Zheng
Journal of Hematology & Oncology (2025) Vol. 18, Iss. 1
Open Access
Expanding the potential of antibody–drug conjugates in gastrointestinal malignancies: beyond HER2 targets
Panagiotis Ntellas, Avani Athauda, Kemmyo Sugiyama, et al.
ESMO Gastrointestinal Oncology (2025) Vol. 8, pp. 100154-100154
Closed Access
Mapping the patent landscape of TROP2-targeted biologics through deep learning
X. D. Yu, Yao Jin, Kunmeng Liu, et al.
Nature Biotechnology (2025) Vol. 43, Iss. 4, pp. 491-500
Closed Access
Synergistic HER2-scFv mediated immunotherapy with Targeted Gemcitabine Delivery Harnessing Biomimetic Composite Nanoparticles for Enhanced Metastatic Tumor Therapy
Xin’an Wang, Wenhui Chu, Fuyu Du, et al.
Materials Today Bio (2025), pp. 101784-101784
Open Access
Smart on-demand drug release strategies for cancer combination therapy
Xiaolin Huang, Mengfei Ji, X L Shang, et al.
Journal of Controlled Release (2025), pp. 113782-113782
Closed Access
Revealing the Anti-Cancer Potential of 1,2,3-Triazole-Isonicotinate Derivatives Targeting EGFR Kinase Inhibition in MCF-7 Cancer Cells: Design, Synthesis, Biological Evaluation, and In Silico Studies
Asma K. Alshamari, Faiza I. A. Abdella, Ayshah Aysh ALrashidi, et al.
Polycyclic aromatic compounds (2025), pp. 1-22
Closed Access
Overcoming Resistance to Checkpoint Inhibitors with Combination Strategies in the Treatment of Non-Small Cell Lung Cancer
Amanda Reyes, Ramya Muddasani, Erminia Massarelli
Cancers (2024) Vol. 16, Iss. 16, pp. 2919-2919
Open Access | Times Cited: 3
Antibody-drug conjugates in metastatic breast cancer: sequencing, combinations and resistances
Lorenzo Guidi, Laura Boldrini, Dario Trapani, et al.
Current Opinion in Oncology (2024)
Closed Access | Times Cited: 3
Page 1 - Next Page

Scroll to top